Pharmacopsychiatry 2012; 45(01): 37-39
DOI: 10.1055/s-0031-1287776
Letter
© Georg Thieme Verlag KG Stuttgart · New York

A Case of Selective Mutism in an 8-Year-Old Girl with Thalassaemia Major after Bone Marrow Transplantation

P. L. Plener
1   Department of Child and Adolescent Psychiatry and Psychotherapy, University of Ulm, Ulm, Germany
,
S. A. Gatz
2   Department of Child and Adolescent Medicine, University of Ulm, Ulm, Germany
,
C. Schuetz
2   Department of Child and Adolescent Medicine, University of Ulm, Ulm, Germany
,
A. G. Ludolph
1   Department of Child and Adolescent Psychiatry and Psychotherapy, University of Ulm, Ulm, Germany
,
M. Kölch
1   Department of Child and Adolescent Psychiatry and Psychotherapy, University of Ulm, Ulm, Germany
› Institutsangaben
Weitere Informationen

Publikationsverlauf

received 16. April 2011
revised 29. Juli 2011

accepted 01. August 2011

Publikationsdatum:
11. Oktober 2011 (online)

Abstract

Selective mutism is rare with a prevalence below 1% in the general population, but a higher prevalence in populations at risk (children with speech retardation, migration). Evidence for treatment strategies is hardly available. This case report provides information on the treatment of selective mutism in an 8-year-old girl with preexisting thalassaemia major. As medications she received penicillin prophylaxis (500000 IE/d) and deferasirox (Exjade; 20–25mg/kg/d), an iron chelator. The preexisting somatic disease and treatment complicated the treatment, as there are no data about pharmacological combination therapy. Psychotherapy in day treatment, supported by the use of the SSRI fluoxetine (10 mg), led to a decrease in the selective mutism score from 33 to 12 points, GAF improved by 21 points. Mean levels of fluoxetine plus norfluoxetine were 287.8 ng/ml without significant level fluctuations.

 
  • References

  • 1 Wong P. Selective mutism: a review of etiology, comorbidities, and treatment. Psychiatry 2010; 7: 23-31
  • 2 Kumpulainen K, Räsänen E, Raaska H et al. Selective mutism among second-graders in elementary school. Eur Child Adolesc Psychiatry 1998; 7: 24-29
  • 3 Elizur Y, Perednik R. Prevalence and description of selective mutism in immigrant and native families: a controlled study. J Am Acad Child Adolesc Psychiatry 2003; 42: 1451-1459
  • 4 Steinhausen HC, Juzi C. Elective mutism: an analysis of 100 cases. J Am Acad Child Adolesc Psychiatry 1996; 35: 606-614
  • 5 Cohan SL, Chavira DA, Shipon-Blum E et al. Refining the classification of children with selective mutism: a latent profile analysis. J Clin Child Adolesc Psychol 2008; 37: 770-784
  • 6 Remschmidt H, Poller M, Herpertz-Dahlmann B et al. A follow-up study of 45 patients with elective mutism. Eur Arch Psychiatry Clin Neurosci 2001; 251: 284-296
  • 7 Hartmann B, Lange M. Evaluationsbogen für das sozialinteraktive Kommunikationsverhalten bei Mutismus. 2006 available at http://www.boris-hartmann.de/sprachtherapie-boris-hartmann/files/evaluationsbogen.pdf
  • 8 Cohan SL, Chavira DA, Stein MB. Practicioner review: psychosocial interventions for children with selective mutism: a critical evaluation of the literature from 1990-2005. J Child PsycholPsychiatry 2006; 47: 1085-1097
  • 9 Kaakeh Y, Stumpf JL. Treatment of selective mutism: focus on selective serotonin reuptake inhibitors. Pharmacotherapy 2008; 28: 214-224
  • 10 Galanello R, Piga A, Forni GL et al. Phase II clinical evaluation of deferasirox, a once-daily oral chelating agent, in pediatric patients with beta-thalassemia major. Haematologica 2006; 91: 1343-1351